Author:
Ray-Coquard I,Favier L,Weber B,Roemer-Becuwe C,Bougnoux P,Fabbro M,Floquet A,Joly F,Plantade A,Paraiso D,Pujade-Lauraine E
Publisher
Springer Science and Business Media LLC
Reference37 articles.
1. ARIAD Pharmaceuticals Inc. ARIAD presents positive efficacy data on AP23573, novel mTOR inhibitor, in phase 2 metastatic endometrial cancer trial [press release]. Available http://phx.corporate-ir.net/phoenix.zhtml?c=118422&p=irol-newsArticle_print&ID=1010401&highlight= (accessed 16 February 2012).
2. Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Bebled M, Spaëth D, Legouffe E, Allouache D, El Khouri C, Pujade-Lauraine E (2012) Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth fact receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 30: 2718–2724.
3. Block M, Fister S, Emons G, Seeber S, Grundker C, Gunthert AR (2010) Antiproliferative effects of antiestrogens and inhibitors of growth factor receptor signaling on endometrial cancer cells. Anticancer Res 30: 2025–2031.
4. Catasus L, D'Angelo E, Pons C, Espinosa I, Prat J (2010) Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations. Mod Pathol 23: 694–702.
5. Catasus L, Gallardo A, Cuatrecasas M, Prat J (2009) Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod Pathol 22: 522–529.
Cited by
87 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献